CRO (Contract Research Organization)
Search documents
药明康德_2025 年三季度业绩回顾_后期小分子研发生产支撑订单增长动能;早期阶段
2025-10-28 03:06
27 October 2025 | 10:57PM HKT Equity Research WuXi AppTec Co. (2359.HK): 3Q25 Earnings review: Order growth momentum supported by late-stage small molecule D&M Early stage During the results call, management provided further granularity on gross margin performance, new order momentum, and sector recovery. Consistent with our initial take, the company raised full-year revenue guidance and reiterated its target for TIDES revenue growth of 80% for the year. Management indicated that guidance for next year's re ...